Lv6
3160 积分 2021-09-07 加入
NL-201 Upregulates MHC-I Expression and Intratumoral T-cell Receptor Diversity, and Demonstrates Robust Antitumor Activity as Monotherapy and in Combination with PD-1 Blockade
11小时前
已完结
Ivonescimab: First Approval
3天前
已完结
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
9天前
已完结
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)
13天前
已关闭
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)
13天前
已完结
An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies
19天前
已完结
Preclinical evaluation of DB-1419, a novel bifunctional and bispecific anti-B7-H3×PD-L1 antibody-drug conjugate
19天前
已完结
DS-3939a: A TA-MUC1-directed Antibody-Drug Conjugate with Broad Anti-Tumor Activity
20天前
已完结
Evaluation the potential of recombinant anti-CD3 nanobody on immunomodulatory function
21天前
已完结
The landscape for radioligand therapies in oncology
22天前
已完结
皖公网安备34019202002308
